Infliximab associated with life-threatening lung infection in a patient with Behcet disease with intestinal and hematopoietic system involvement

A case report

Yong Chen, MD, PhD,b Yan Shen, MDa, Hai-fen Ma, MDa, Jian-Fei Cai, MDa, Yan-qin Hua, MDb, Jun Zou, MDa, Jian-long Guan, MD, PhDa,∗

Abstract
Rationale: Tumor necrosis factor (TNF-α) participates in the pathophysiology of Behcet’s disease (BD) and myelodysplastic syndrome (MDS). Infliximab is recommended for the most severe type of BD, however, there is little evidence for its effectiveness in BD associated MDS.

Patient concerns: A 46-year-old female, initially diagnosed with intestinal BD and leukopenia was later diagnosed as MDS. Treatment with infliximab and other immunoregulators lead to life-threatening pneumonia.

Diagnosis: Intestinal BD associated with MDS involving trisomy 8.

Interventions: The patient initially treated with methylprednisolone, thalidomide, cyclosporine A, and infliximab, which lead to severe lung infection. Therefore, the patient was transferred to Intensive Care Unit for life supportive, anti-infection and immune improving therapy.

Outcomes: The patient survived from the lung infection. With combination of methylprednisolone, thalidomide and cyclosporine A, the patient recovered from her intestinal ulceration and MDS manifestations.

Lessons: Infliximab treatment may not benefit a patient with BD associated with MDS but place the patient at risk of infection.

Abbreviations: BD = Behcet disease, C = complement, CH50 = complement hemolysis 50% assay, CRP = C-reactive protein, ESR = erythrocyte sedimentation rate, Ig = immunoglobulin, MDS = myelodysplastic syndrome, RBC = red blood cell, TNF = tumor necrosis factor, WBC = white blood cell.

Keywords: autoimmune, infection, infliximab, TNF-α, trisomy 8

1. Introduction
Behcet disease (BD) is a systemic autoimmune disorder, characterized by recurrent oral and genital ulceration, eye inflammation, and erythema nodosum. The disease may involve multiple systems: gastrointestinal, neurological, vascular, skeletal, and hematopoietic.[1] Tumor necrosis factor (TNF-α) plays a central role in both the inflammatory and immune responses. Blockade with anti-TNF agents are important tools in the management of a variety of autoimmune disorders. TNF-α appears to participate in the mechanism of BD; however, there is a paucity of adequate clinical trials. Based on case reports and case series, BD is an off-label indication of anti-TNF-α agents.[2] Anti-TNF-α therapy such as infliximab appears to be effective in treatment of severe and refractory BD manifestations.[3]

Infliximab, common to drugs in the class of TNF inhibiting immunosuppressants, has multiple potential adverse effects, some are life threatening. The most severe are serious infections, reactivation of hepatitis B, reactivation of tuberculosis, lethal hepatosplenic T-cell lymphoma, drug-induced lupus erythematosus, and demyelinating central nervous system disorders.[4] We present a rare case of BD with intestinal ulceration, arthritis, and hemocytopenia. The patient experienced a life-threatening lung infection during her treatment by infliximab combined with other immunoregulators.

2. Case presentation
A 46-year-old female presented to our institute on 19 December, 2016, complaining of recurrent oral aphthous ulceration of 10 years’ duration. She had 2 to 3 attacks per year, lasting 1 to 2 weeks. In the past 2 years, she complained of oral ulcerations almost monthly accompanied with 2 episodes of genital ulceration. The patient also complained of right ankle pain after
mild edema in the lower part of the leg. Magnetic resonance imaging (MRI) of her right ankle revealed a 10 mm × 5 mm ulceration in the ileoecal region; (B) endoscopy revealing a 10 mm × 5 mm ulceration in the ileocecal region; (C) karyotype analysis for bone marrow cells revealing 47, XX, +8. Figure 1.

3. Discussion

We presented a case of BD with joint, intestinal, and hematopoietic system involvement. BD is a chronic multisystem inflammatory disease, first described in the 1930s by Hulusi Behcet. BD is also known as Silk Route disease due to its high incidence in the countries of the eastern Mediterranean and the eastern rim of Asia.[5] However, approximately 2000 years ago, a Chinese doctor named Zhang Zhongjing described very similar symptoms, and named them Huhuo disease in his work Synopsis of Golden Chamber.[6]

The incidence of intestinal BD is around 13%. In our institution, 63% of the intestinal ulcers were found in the ileocecum.[7] Although BD and MDS are distinct disease entities, several studies have identified a relationship between them, especially in the context of intestinal BD. Previous reports have also revealed that trisomy 8 appears to play an important role in these disorders.[8,9]

There is evidence that TNF-α inhibition by infliximab is effective for rapid improvement and maintenance of remission in intestinal BD.[10,11] Vallet et al reported that infliximab and alemtuzumab were effective in treating severe or refractory BD symptoms, including refractory ocular, mucocutaneous, joint, gastrointestinal, central nervous system, and cardiovascular manifestations. These authors claim that anti-TNF-α therapy is appropriate for all severe and refractory BD manifestations.[12] It is unclear if this is the case for BD associated with MDS.
TNF-α is a proinflammatory cytokine that inhibits normal hematopoiesis and induces programmed cell death in both normal total bone marrow cells and normal CD34+ cells. Studies have suggested an important role of TNF-α in the pathophysiology of MDS. Abnormal release of inflammatory cytokines including TNF-α has been reported in cytopenia and disease progression in MDS. The effectiveness of infliximab for treatment of MDS is a matter of dispute. Toyonaga et al reported 2 cases of intestinal BD with MDS and trisomy 8 that did not respond to infliximab. In a thorough review of 33 cases, 20 (60.6%) showed temporary improvement of BD symptoms, 10 (30.3%) worsened, and 3 (9.1%) showed no change. Therefore, infliximab might not be effective for treatment of intestinal BD with MDS involving trisomy 8.

Colombel et al evaluated short- and long-term safety of infliximab in 500 Crohn disease patients. Forty-one (8.2%) patients experienced infection attributed to infliximab, of which 20 were serious infections. Two suffered fatal sepsis, 8 had pneumonia (of which 2 cases were fatal), 6 had viral infections, 2 had abdominal abscesses requiring surgery, 1 had arm cellulitis, and 1 had histoplasmosis. MDS is associated with disordered innate immune and inflammatory signaling possibly increasing the risk of infection. However, there are little data to support this.

We report a BD patient with joint and intestinal involvement associated with MDS in the context of trisomy 8. During her treatment with infliximab, she suffered leukopenia and the onset of herpes zoster, suggesting decreased immune function and increased susceptibility to infection. We believe her life-threatening pneumonia could be attributed to infliximab treatment. After 1 month of intensive care, the patient recovered. It hypothesized that MDS is an autoimmune disorder. Thalidomide and cyclosporine A have been reported to be effective for MDS. Conventional immunoregulators for intestinal BD might have had favorable effects for MDS in this case.

### 4. Conclusion

The history of oral and genital ulceration, combined with the positive pathergy test in this case met diagnostic criteria for BD. On endoscopy, the patient was found to have intestinal ulceration. The history of low WBCs, characteristic bone marrow smear, and karyotype analysis suggested the diagnosis of MDS. Although TNF-α plays an important role in the development in MDS, the effectiveness of treatment with infliximab to treat MDS is under dispute. Case reports reveal unfavorable results of anti-TNF-α therapy for BD associated with MDS. Considering the fact that MDS patients have reduced immunity, infliximab might not effect for BD associated with MDS patient, and in fact might place this type of patient at risk of infection.

### References

[1] Davatchi F, Assaad Khalil S, Calamia KT, et al. The International Criteria for Behcet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 2014;28:338–47.
Sánchezcano D, Callejasrubio JL, Ruizviilaverde R, et al. Off-label uses of anti-TNF therapy in three frequent disorders: Behçet’s disease, sarcoidosis, and noninfectious uveitis. Mediators Inflamm 2013;2013:286857.

Vallet H, Riviere S, Sanna A, et al. Efficacy of anti-TNF alpha in severe and/or refractory Behcet’s disease: multicenter study of 124 patients. J Autoimmun 2015;62:67–74.

Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19–31.

Ambrose NL, Haskard DO. Differential diagnosis and management of Behcet syndrome. Nat Rev Rheumatol 2013;9:79–89.

Yong C, Jianfei C, Jun Z, et al. Pi in traditional Chinesemedicine refers to pancreas while not spleen. Negative 2017;8:35–8.

Yong C, Wenjing L, Jun Z, et al. Intestinal pathological changes in Behçet’s disease: a clinical retrospective study. Fudan Univ J Med Sci 2017;44:493–7.

Kawano S, Hiraoka S, Okada H, et al. Clinical features of intestinal Behcet’s disease associated with myelodysplastic syndrome and trisomy 8. Acta Med Okayama 2015;69:365–9.

Toyonaga T, Nakase H, Matsuara M, et al. Refractoriness of intestinal Behçet’s disease with myelodysplastic syndrome involving trisomy 8 to medical therapies—our case experience and review of the literature. Digestion 2013;88:217–21.

Iwata S, Saito K, Yamaoka K, et al. Effects of anti-TNF-alpha antibody infliximab in refractory enterob-ehcet’s disease. Rheumatology 2009;48:1012–3.

Lee JH, Cheon JH, Jeon SW, et al. Efficacy of infliximab in intestinal Behcet’s disease: a Korean multicenter retrospective study. Inflamm Bowel Dis 2013;19:1833–8.

Baron F, Suciu S, Amadori S, et al. Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group. Haematologica 2012;97:529–33.

Braun T, Fenaux P. Myelodysplastic Syndromes (MDS) and autoimmune disorders (AD): cause or consequence? Best Pract Res Clin Haematol 2013;26:327–36.

Stasi R, Amadori S, Newland AC, et al. Infliximab chimeric antitumor necrosis factor-a monoclonal antibody as potential treatment for myelodysplastic syndromes. Leuk Lymphoma 2005;46:509–16.

Gañán-Gómez I, Wei Y, Starczynowski DT, et al. Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes. Leukemia 2015;29:1458–69.

Komrokji RS, Kulasekararaj A, Abh NHA, et al. Autoimmune diseases and myelodysplastic syndromes. Ann J Hematol 2016;91:E280–3.

Wang J, Qin T, Xu Z, et al. 255 response to thalidomide and cyclosporine in patients with lower-risk myelodysplastic syndrome without isolated del(5q). Leuk Res 2015;39:S127.